---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-071296"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T22:59:05.998056+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Relmada's RELIANCE III MDD trial failed; RELIANCE I results at risk from similar enrollment issues

## Summary
- RELIANCE III monotherapy trial failed; placebo group mean change of 23 points at one high-enrolling site; 30% of patients from such sites.
- RELIANCE I adjunctive trial results by year-end 2022; 40% of patients from same high-enrolling sites, raising risk of similar failure.
- RELIANCE II adjunctive trial results delayed to 2023; protocol changes being implemented.
- Q3 2022 net loss $39.4M ($1.31/diluted) vs $42.6M ($2.44) prior year; cash $184.2M.
- Company states it has financial flexibility to continue advancing REL-1017.

## SEC filing metadata
- accession: 0001213900-22-071296
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000121390022071296/0001213900-22-071296-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000121390022071296/ea168442-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-071296
- JSON: https://secwatch.observer/filing/0001213900-22-071296.json
- Plain text: https://secwatch.observer/filing/0001213900-22-071296.txt

## Key facts
- Earnings Releases
  RELMADA THERAPEUTICS, INC. reported the nine months ended September 30, 2022 results: net income $119.1 million, EPS $4.04 per share.
  - Period: the nine months ended September 30, 2022
  - Net income: $119.1 million
  - EPS: $4.04 per share
  - Result: preliminary results
  source text: Net loss for the nine months ended September 30, 2022 and 2021 was $119.1 million and $91.4 million, respectively. The Company had a net loss of $4.04 and $5.36 per share for the nine months ended September 30, 2022 and 2021, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1553643/000121390022071296/0001213900-22-071296-index.htm
- Earnings Releases
  RELMADA THERAPEUTICS, INC. reported the three months ended September 30, 2022 results: net income $39.4 million, EPS $1.31 per diluted share.
  - Period: the three months ended September 30, 2022
  - Net income: $39.4 million
  - EPS: $1.31 per diluted share
  - Result: preliminary results
  source text: The net loss for the three months ended September 30, 2022, was $39.4 million, or $1.31 per diluted share, compared with a net loss of $42.6 million, or $2.44 per diluted share, for the three months ended September 30, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1553643/000121390022071296/0001213900-22-071296-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.